Related references
Note: Only part of the references are listed.Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A. Nauck et al.
DIABETOLOGIA (2016)
Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation
Yingyu Feng et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2016)
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
M. Odawara et al.
DIABETES OBESITY & METABOLISM (2016)
Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis
Wayne H. -H. Sheu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES
Matthew P. Gilbert et al.
ENDOCRINE PRACTICE (2016)
Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress
Jieqiong He et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Liraglutide attenuates the osteoblastic differentiation of MC3T3-E1 cells by modulating AMPK/mTOR signaling
Xiong-Ke Hu et al.
MOLECULAR MEDICINE REPORTS (2016)
c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines
Elda Leonor Pacheco-Pantoja et al.
Purinergic Signalling (2016)
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin
Jingru Meng et al.
STEM CELL REPORTS (2016)
The bone-preserving effects of exendin-4 in ovariectomized rats
Han-xiao Sun et al.
ENDOCRINE (2016)
Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes
Renyuan Li et al.
ACTA DIABETOLOGICA (2015)
Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice
M. Pereira et al.
BONE (2015)
Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
Johanna H. M. Driessen et al.
CALCIFIED TISSUE INTERNATIONAL (2015)
Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
Johanna H. M. Driessen et al.
CALCIFIED TISSUE INTERNATIONAL (2015)
Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice
Shugo Sasaki et al.
DIABETOLOGIA (2015)
Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus
Sity Aishah Mansur et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Eva W. Iepsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Relationships Among the Metabolic Syndrome, Bone Mineral Density, Bone Turnover Markers, and Hyperglycemia
Rabia Terzi et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2015)
Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro
Hao Zhou et al.
SCIENTIFIC REPORTS (2015)
Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats
Han-xiao Sun et al.
JOURNAL OF DIABETES (2015)
Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength
A. Mieczkowska et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes
Nan Lu et al.
PLOS ONE (2015)
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials
Bin Su et al.
ENDOCRINE (2015)
Expression of glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells
Emina Aoyama et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials
Guillaume Mabilleau et al.
JOURNAL OF DIABETES (2014)
Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
Yun Kyung Jeon et al.
ENDOCRINOLOGY AND METABOLISM (2014)
Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats
Xue Ma et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor
Guillaume Mabilleau et al.
JOURNAL OF ENDOCRINOLOGY (2013)
Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes
Ju-Young Kim et al.
LIFE SCIENCES (2013)
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice
Benjamin J. Lamont et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
M. C. Bunck et al.
DIABETES OBESITY & METABOLISM (2011)
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
Bernardo Nuche-Berenguer et al.
JOURNAL OF ENDOCRINOLOGY (2011)
Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort
Noriko Yoshimura et al.
MODERN RHEUMATOLOGY (2011)
Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow
C. Sanz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Presence of a Functional Receptor for GLP-1 in Osteoblastic Cells, Independent of the cAMP-Linked GLP-1 Receptor
Bernardo Nuche-Berenguer et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
Bernardo Nuche-Berenguer et al.
REGULATORY PEPTIDES (2010)
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Bernardo Nuche-Berenguer et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Characterization of the Structural Features and Interactions of Sclerostin MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION
Vaclav Veverka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Kristine J. Hare et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
Chizumi Yamada et al.
ENDOCRINOLOGY (2008)
Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation
Zhengyu Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Effects of continuous activation of vitamin D and Wnt response pathways on osteoblastic proliferation and differentiation
Yan-chuan Shi et al.
BONE (2007)
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis
P. Vestergaard
OSTEOPOROSIS INTERNATIONAL (2007)
Expression profiling and functional analysis of Wnt signaling mechanisms in mesenchymal stem cells
SL Etheridge et al.
STEM CELLS (2004)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Pluripotency of mesenchymal stem cells derived from adult marrow
YH Jiang et al.
NATURE (2002)
Mechanism of circadian variation in bone resorption
NH Bjarnason et al.
BONE (2002)
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers
EM Hauge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Bone mineral changes in obese women during a moderate weight loss with and without calcium supplementation
LB Jensen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Share Paper
